Denca is under control at SAFC plant in Scotland

Published: 6-Jun-2011
Manufacturing Pharmaceutical

Will supply full control system for IPB2 facility at Irvine

Automation control systems specialist Denca Controls has been awarded the E&I controls contract for the new IPB2 facility being designed by laboratory and cleanroom specialist T Squared for SAFC, a leader in biochemical and organic chemical products, based in Irvine, Scotland.

The project involves building and automating a cell culture media, reagents and buffer solutions manufacturing system, CIP system, WFI/SIP system and filling system at the SAFC facility.

Denca, based in Widnes, Cheshire, will supply a full control system consisting of E&I design, manufacture of system control panels, including motor control panel, PLC/instrument control panel and multiple remote I/O, solenoid, HMI panels, system software and associated validation documentation to GAMP (Good Automated Manufacturing Practices), installation and testing/commissioning through to client handover.

See more

You may also like

Manufacturing

Denca designs control system for pharma facility

Read more
Project in Liverpool worth £500,000

Trending Articles

  1. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding high-volume pre-filled syringe capabilities to its existing fill-finish operations in Switzerland and Livron
  2. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  3. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
  4. Marchesini Group at Interpack 2026 Sustainability, primary packaging, aseptic production, robotics and digital innovation at the heart of this edition
  5. L.B. Bohle hosts successful continuous manufacturing workshop in Brazil Focus on continuous wet granulation and drying for research, development and small-scale production

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Denca designs control system for pharma facility

Project in Liverpool worth £500,000
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Manufacturing

Labtex - Fresh thinking and innovative solutions

Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
Manufacturing

Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform

The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Manufacturing

Symbiosis completes full ICH climatic zone coverage with new stability chamber addition

Sterile injectable CDMO Symbiosis Pharmaceutical Services has installed a 30°C stability chamber at its Stirling facility, completing its coverage of all four ICH-defined climatic zones and strengthening its commercial drug product supply capabilities for global markets
Subscribe now